Guided Therapeutics (GTHP) Total Current Liabilities (2010 - 2026)

Guided Therapeutics has disclosed Total Current Liabilities across 17 years of filings, most recently posting $6.2 million for Q2 2026.

• In Q2 2026, Total Current Liabilities fell 3.26% year-over-year to $6.2 million; the TTM figure through Jun 2026 stood at $6.2 million (down 3.26% YoY), while the FY2025 annual figure was $6.6 million, up 7.81% from the prior year.
• Total Current Liabilities came in at $6.2 million for Q2 2026 at Guided Therapeutics, up from $6.0 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $6.6 million in Q4 2025 to a low of $4.0 million in Q1 2023.
• Average Total Current Liabilities over 5 years is $5.6 million, with a median of $5.8 million recorded in 2024.
• Year-over-year, Total Current Liabilities slumped 40.96% in 2022 and soared 33.45% in 2024.
• Over 5 years, Total Current Liabilities stood at $4.9 million in 2022, then retreated by 1.23% to $4.8 million in 2023, then grew by 27.99% to $6.2 million in 2024, then increased by 7.81% to $6.6 million in 2025, then fell by 7.04% to $6.2 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $6.2 million in Q2 2026, $6.0 million in Q1 2026, and $6.6 million in Q4 2025.